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TO THE EDITOR
Over the last decades therapy of chronic myeloid leukemia (CML) consisted of hydroxyurea or interferon. Recently, the selective competitive inhibitor of the BCR-ABL protein tyrosine kinase imatinib mesylate (formerly STI571; Novartis, Basel, Switzerland), was introduced into the therapy of CML. 1, 2 However, several different mechanisms of resistance to imatinib have been observed. 3, 4 The occurrence of karyotype abnormalities in addition to the Ph translocation is associated with acceleration of the disease and has also been shown to play a role in CML patients resistant to imatinib. 5 An increase in the number of additional cytogenetic changes and the development of nonstandard karyoytpe abnormalities has been reported in interferontreated patients. 6, 7 To estimate the occurrence of secondary karyotypic changes and their impact on response to imatinib therapy, we investigated 140 patients with BCR-ABL positive CML prior to and during treatment with imatinib.
One hundred and twenty-eight patients were analyzed directly prior to treatment with imatinib and 12 patients at an interval of 1 to 6 months before start of therapy. In most patients cytogenetic analyses were carried out at intervals of 3 months. Patients were analyzed two to six times (median two) during imatinib therapy with a follow-up time of 3 to 24 months (median 12 months). Overall, 1555 months of imatinib treatment were monitored. Twenty patients were in blast crisis, 34 patients in accelerated phase, and 86 in chronic phase at start of therapy with imatinib. Patients with chronic phase were either resistant or intolerant to interferon therapy.
At start of treatment 131 patients showed a standard Ph translocation, while in eight patients a variant Ph translocation and in one case a Ph-negative, BCR-ABL-positive CML was observed. In 109 patients the Ph translocation was the sole karyotype abnormality, while in 31 patients additional karyotype changes were observed prior to imatinib therapy.
Cytogenetic response was defined according to the percentage of Ph-positive metaphases identified by chromosome banding analysis: complete response: 0% Ph positive metaphases detected; partial response: between 1% and 34%; minor response: between 35% and 95%; no response: more than 95% Ph-positive metaphases detected. 8 For each patient the best cytogenetic response achieved during imatinib treatment was used for evaluation. Patients with karyotype changes in addition to the Ph translocation prior to imatinib therapy had a significantly lower rate of cytogenetic responses than patients with the Ph translocation as the sole cytogenetic abnormality (48.4% vs 69.7%, P = 0.028) ( Table 1) . Patients with additional chromosome abnormalities were more frequently in blast crisis than those without (41.9% vs 6.4%, P Ͻ 0.0001) and were less often in chronic phase (35.5% vs 68.8%, P = 0.0008). With respect to the stage of the disease 46 of 86 patients in chronic phase (53.5%) but only six of 20 cases in blast crisis (30%) showed a complete cytogenetic response (P = 0.058). Only 20 of 86 patients in chronic phase (23.3%) but 11 out of 20 cases in blast crisis were cytogenetic non-responders (55%) (P = 0.005). These response data are in line with published data from phase I and phase II trials confirming the lower response rates to imatinib treatment in cases with blast crisis. 1, 9 With respect to cytogenetics, our study for the first time shows an association between response to imatinib treatment and chromosomal aberrations in addition to the Philadelphia translocation. These data were confirmed by univariate analyses of correlations between the respective end points, ie complete response, major response, and no response, and the existence of additional cytogenetic aberrations Leukemia (P = 0.08, P = 0.08 and P = 0.03, respectively) and the disease stage (for all analyses P Ͻ 0.05). However, within different disease stages additional chromosome aberrations did not influence response to therapy (for all analyses P Ͼ 0.20). Multivariate analyses confirmed these results and revealed an accelerated phase and blast crisis as major prognostic factors for complete response (P = 0.005 and NS), major response (P Ͻ 0.001 and P = 0.02) and no response (P = 0.003 and P = 0.05).
During treatment with imatinib 18 patients developed new chromosome aberrations 2 months to 20 months after start of therapy (median 10.5 months). Of these patients, 72.2% were resistant to imatinib. Eleven patients showed one to three of the most common additional abnormalities +Ph (n = 5), +8 (n = 8) or i(17)(q10) (n = 2). The aberrations observed in the other seven patients were del(7)(q11); t(X;2)(p11.4;q21); dic(17;18)(p11;p11); del(17)(p11); dup(1)(q21q44); ider(22)(q10)t(9;22); and del(1)(p35),der(6)t(6;22)(q27;q11), der(18)t(18;22)(p13;q?) in one case each. Detailed data on these 18 patients are shown in Table 2 . Patients who showed no cytogenetic response to imatinib treatment showed new karyotype changes during the course of the disease more often than others (26.5% vs 5.5%, P = 0.0002) ( Table 1 ). In nine of 31 patients with additional abnormalities prior to imatinib treatment loss of the additional abnormalities occurred and the Ph translocation was the sole abnormality under treatment with imatinib (clonal regression). None of these patients showed a complete cytogenetic response. In two of these patients loss of aberrations occurred that were present prior to treatment but also gain of new abnormalities was detected.
Thus, 12.9% of patients developed additional karyotype changes within 2 to 20 months after start of therapy with imatinib. An increase in the number of additional cytogenetic changes and the development of non-standard karyotype abnormalities has been reported in interferon-treated patients. 6, 7 Johansson et al 7 reported that 60% to 80% of patients without treatment or treatment with hydroxyurea or busulfan or a combination of both showed so-called major or minor route changes (+8, +Ph, i(17)(q10), +19, −Y, inv(3)(q21q26), t(3;21)(q26;q22), −7, t(8;21)(q22;q22), t(15;17)(q22;q12), inv(16)(p13q22), −17, +17,+21) while in only 50% of patients with clonal evolution during interferon treatment was one of these abnormalities observed. In the interferon-treated patients unusual secondary abnormalities were described with del(7p) and del(13q) being recurrent ones occurring at significantly higher frequencies than in CML without treatment or after busulfan or hydroxyurea therapy. Hild et al 6 also described a similar tendency of uncommon secondary aberrations and a frequent clonal progression during chronic phase among interferon-treated patients. In our study of patients treated with imatinib 61.1% showed one of the major or minor route changes. No recurring imatinib-associated secondary change was identified in our cohort. The frequency of the development of new cytogenetic changes during imatinib therapy was not increased, as clonal evolution occurred in patients in chronic phase during imatinib treatment with the same frequency as has been reported in untreated patients (9.3% vs 8.8%). 10 New chromosome abnormalities occurred less frequently during imatinib therapy than has been reported during interferon treatment (12.9% vs 18%) but more frequently than reported during treatment with busulfan or hydroxyurea (8%).
Beside clonal evolution within the Ph-positive clone the occurrence of a clone without a Ph translocation but a trisomy 8 was observed in four cases in this cohort. Interestingly, during the course of the disease the Ph-positive clone decreased and the Ph negative clone with +8 increased in two of these patients. One case showed a complete cytogenetic response for the Ph-positive clone but at the same time a trisomy 8 in 8% of interphase nuclei and 35% of metaphases. The clinical impact of these new Ph-negative clones is unclear and has to be evaluated in further studies.
In conclusion, the cytogenetic response to imatinib therapy was related to the presence of additional karyotype changes as well as to the disease stages, but response did not differ according to additional cytogenetic abnormalities within the respective disease stage. Therefore, the presence of additional chromosome abnormalities per se does not fully predict resistance to imatinib therapy. Furthermore, patients without a cytogenetic response to imatinib were more likely to develop additional karyotype changes during the course of the disease. The incidence and the pattern of abnormalities occurring during treatment with imatinib is comparable to the clonal evolution during the natural course of the disease or during treatment with hydroxyurea or busulfan and does not show a specific pattern for imatinib treatment. The development of Ph-negative clones seems to be more frequent in patients treated with imatinib than has been observed during other therapy regimens.
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Imatinib mesylate-induced molecular remission of Philadelphia chromosome-positive myelodysplastic syndrome
Leukemia ( The presence of certain abnormal karyotypes at diagnosis is associated with a greater probability of transformation into acute myeloid leukemia (AML), 1 with a notoriously poor response to conventional chemotherapy. The Philadelphia chromosome (Ph) is generated by a specific translocation involving chromosomes 9 and 22, and is found in 95% of patients with chronic myeloid leukemia (CML) and some acute leukemias. The resultant BCR-ABL mRNA encodes the BCR-ABL oncoprotein, which has greatly enhanced tyrosine kinase activity and a central role in the pathogenesis of these disorders. 2 Imatinib mesylate, a novel tyrosine kinase inhibitor selective for the BCR-ABL oncoprotein, has recently been shown to be effective in CML with some patients achieving complete cytogenetic remissions. 3 Ph+ MDS is uncommon, with less than 20 cases described in the literature worldwide, 4 and responds poorly to conventional chemotherapy. Here, we report the first case of Ph+ MDS successfully treated with the novel tyrosine kinase inhibitor imatinib mesylate.
A 67-year-old woman presented in April 1999 with mild pancytopenia: hemoglobin 115 g/l, WBC 3.4 × 10 9 /l (neutrophils 1.2, lymphocytes 1.6, basophils 0.0, eosinophils 0.1, blasts 0.3 and myelocytes 0.2 ϫ 10 9 /l) and platelets 111 × 10 9 /l. Blood smear examination revealed anisopoikilocytosis and hypogranulated pseudo Pelger-Huët neutrophils. There was no splenomegaly or lymphadenopathy on examination. LDH was elevated at 1163 U/l (normal range 80-180 U/l). Assays for vitamin B12 and folate were within normal ranges. Bone marrow (BM) smear at diagnosis showed a myeloid: erythroid ratio of 3:1, marked trilineage dysplasia and 10% blasts on a 500 cell differential count. Overall cellularity was moderately increased, with stainable iron present. Dyserythropoiesis was prominent with multinucleated cells, internuclear bridging and megaloblastoid nuclei. No ringed sideroblasts were seen. Frequent hypolobulated micromegakaryocytes were observed, with occasional bizarre nuclear patterns in larger forms. The disorder was classified as de novo MDS, subtype refractory anemia with excess blasts type 2 (RAEB-2), accord- ing to the WHO Classification of Tumours.
5 BM cytogenetics at diagnosis showed 29/30 Ph+ and 1/30 46XX metaphases with no additional karyotypic abnormalities. Serial blood films demonstrated early disease progression (a rise in the percentage of blasts from 9% to 20%), and treatment was commenced (comprising daunorubicin 50 mg/m 2 for 3 days and cytosine 100 mg/m 2 bd for 8 days). The marked reduction in percentage of Ph+ metaphases (to 6%) and blasts (to 3%) and improvement in BM dysplastic features observed after the first cycle were not sustained (Figure 1 ), despite two further cycles of chemotherapy followed by a trial of ␣-interferon (IFN, commenced in view of the Ph+ status). Serial BM examinations thereafter showed a progressive increase in the blast population. Prior to commencing imatinib, a repeat BM showed 22% blasts, ongoing features of triline-
